Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Not all rewards are considered taxable income. Discover what qualifies to keep your finances in check and avoid penalties.
12,857 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Powell Industries may fly under the radar, but patient investors can uncover a potential opportunity. This guide brea...
Barclays slashed Molson Coors' price target to $40, underscoring earnings headwinds as the brewer anticipates a tough...
Geopolitical tensions around Iran and Qatar could reshape global LNG supply. This article explains the potential mark...
As market conditions shift in 2026, many 401(K) accounts look solid on paper but lag in real terms. This report highl...
Fannie Mae and Freddie Mac unveiled a wave of condo lending changes, aimed at stabilizing costs and risk. The new rul...
A nationwide poll reveals broad demand for online safeguards for children, paired with deep mistrust of current laws ...
The Dow rose above a key threshold—49,683.30—on Thursday, putting it on a path to officially exit correction territor...
AST SpaceMobile has been a wild ride for investors. This guide explains why spacemobile impossible ignore right is a ...
As Zillow prepares for 2026 earnings season, investors crave clarity on growth, margins, and how the housing cycle co...
Nasdaq welcomes the 21Shares Canton Network ETF, the latest milestone in the ongoing crypto ETF surge. The fund aims ...
Warner Bros Discovery's 2026 earnings call transcript offers more than quarterly figures. This analysis breaks down t...